Therapeutic Development in Segmental Demyelination
Project Number5I01BX003385-05
Former Number5I01BX003385-03
Contact PI/Project LeaderLI, JUN
Awardee OrganizationJOHN D DINGELL VA MEDICAL CENTER
Description
Abstract Text
DESCRIPTION (provided by applicant):
Demyelination shunts depolarizing current out of the nerve. As a result, nerve conduction of action potentials can be slowed or even eliminated. The later is known as conduction block. This change causes neurological disabilities such as sensory loss, vision loss, and limb paralysis in a variety of neurological diseases. We have found that patients and mice with FIG4 deficiency develop a demyelinating neuropathy. This demyelination closely recapitulates features in acquired demyelinating diseases. The FIG4-deficient cells exhibit lysosomal membrane fission defect with an abnormally suppressed efflux of intralysosomal Ca2+ through a lysosomal Ca2+ channel. These observations lead us to propose the hypothesis below. Hypothesis: FIG4 deficiency deactivates Ca2+-channels on lysosomal membranes and prevents Ca2+ release from lysosomes. This, in turn, impairs lysosomal membrane trafficking (lysosomal fission defect), leading to segmental demyelination. Toward this end, we propose the following specific aims. Specific Aim 1. To test the hypothesis that FIG4 deficiency suppresses lysosomal fission by blocking the efflux of intralysosomal Ca2+ in myelinating Schwann cells. Specific Aim 2. To determine whether FIG4-deficiency in Schwann cell sensitizes the cell to demyelination. In this aim, we will utilize Fig4 conditional knockout mice to examine how the impaired lysosomal Ca2+-homeostasis in Fig4-/- Schwann cells may sensitize the cells to demyelination. Specific Aim 3. To test the hypothesis that FIG4 in myelinating Schwann cells is required for remyelination. Significance of lysosomal membrane trafficking in de/remyelination is essentially unexplored. Our results have demonstrated a novel signaling pathway in FIG4 deficiency that appears to be critical in lysosomal membrane trafficking and demyelination. Since demyelination in Fig4-/- nerves recapitulates key features of acquired demyelinating diseases, results from this project are also relevant to other acquired demyelinating disorders. Furthermore, our preliminary results suggest a high probability in developing therapeutic interventions for demyelination in FIG4 deficiency.
Public Health Relevance Statement
PUBLIC HEALTH RELEVANCE:
Demyelination is a primary pathology in a long list of neurological disorder, including multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, Lewis- Sumner syndrome, and Guillain-Barre Syndrome. Collectively, they are highly prevalent. Our study will utilize the FIG4 deficient mice to explore molecular mechanisms responsible for the demyelination. In addition, therapeutic strategy will also be developed to prevent the demyelination.
NIH Spending Category
No NIH Spending Category available.
Project Terms
Action PotentialsAdultAllelesAxonBlindnessBuffersCellsCharcot-Marie-Tooth DiseaseChronic Inflammatory Demyelinating PolyneuropathyDefectDemyelinating DiseasesDemyelinating PolyneuropathyDemyelinationsDevelopmentDown-RegulationDynaminExcisionExhibitsFailureFlow CytometryGuanosine Triphosphate PhosphohydrolasesGuillain-Barré SyndromeHomeostasisHumanImpairmentKnockout MiceLeadLigandsLimb structureLysosomesMembraneMethodsMissense MutationMolecularMultifocal Motor NeuropathyMultiple SclerosisMusMutationMyelinNAADPNerveNerve DegenerationNeural ConductionNeurologicNeuronsNeuropathyOrganellesParalysedPathogenicityPathologicPathologyPatientsPhosphatidylinositolsPhospholipidsPhosphoric Monoester HydrolasesPlayPrincipal InvestigatorProbabilityProtein BiosynthesisProteinsPublicationsRoleSchwann CellsSensoryShunt DeviceSignal PathwaySpecificitySurfaceSyndromeTestingTherapeuticTherapeutic Interventionconditional knockoutdisabilityin vivoinorganic phosphateloss of functionloss of function mutationmutantnerve injurynervous system disordernovelpatient subsetspreventprotein complexpublic health relevanceremyelinationscaffoldtherapeutic developmenttrafficking
No Sub Projects information available for 5I01BX003385-05
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5I01BX003385-05
Patents
No Patents information available for 5I01BX003385-05
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5I01BX003385-05
Clinical Studies
No Clinical Studies information available for 5I01BX003385-05
News and More
Related News Releases
No news release information available for 5I01BX003385-05
History
No Historical information available for 5I01BX003385-05
Similar Projects
No Similar Projects information available for 5I01BX003385-05